Venezuelan govt increasing control over pharmaceutical sector

14 August 2012

Venezuela’s national government has changed its policy with regard to the pharmaceutical sector. This year, government authorities have taken a number of steps, stripping the sector of its "priority" treatment, writes Roberto Deniz in the El Universal newspaper.

The Venezuelan pharmaceutical market is the third largest in Latin America, and was valued at $6.8 billion in 2010, an increase of 32.7% on the previous year.

Last week, the government put 70% of final products from the pharmaceutical and laboratory sector in list 2 of the Foreign Exchange Administration Commission (Cadivi). Therefore, the requirements to import these products increased and now the pharmaceutical sector should process the Non-Production certificate (CNP) before requesting dollars.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Generics